Vertex Pharmaceuticals (VRTX) news

Nasdaq unofficially closes down 124.63 points, or 0.47 percent, at 26,416.72

The Nasdaq Composite unofficially closed down 124.63 points, or 0.47 percent, at 26,416.72 on Wednesday, reflecting ongoing selling pressure in the technology-heavy index. This decline follows a volatile session in which the index initially dropped sharply before staging a partial recovery. Earlier…

Coatue Management adds SPCX, INTC, CBRS, FPS, HUT in 2Q: 13F

Coatue Management LLC, a prominent hedge fund, disclosed its latest portfolio updates in its 13F filing for the quarter ending December 31, 2025. The firm added several new positions in the second quarter of 2026, including SPCX, INTC, CBRS, FPS, and HUT. These additions reflect the firm’s…

Vertex Pharmaceuticals Incorporated: BofA Global Research adds stock to its US 1 list

Bank of America has added Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) to its US 1 List, top investment ideas in the US . The US 1 List is composed of Buy-rated stocks identified by the bank’s fundamental equity research analysts, with the goal of delivering strong long-term performance .…

Vertex Pharmaceuticals Incorporated: BofA Global Research raises price objective to $672 from $605

BofA Global Research has raised its price target for Vertex Pharmaceuticals (VRTX) to $672 from $605, maintaining a "Buy" rating on the stock. The adjustment follows recent developments, including a failed drug trial by Vertex’s competitor Sionna Therapeutics (SION), which led to a significant drop…

Jefferies raises target price to $633 from $610 for Vertex Pharmaceuticals Incorporated